Cite
HARVARD Citation
Samaniego, F. et al. (2021). Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma. Leukemia & lymphoma. 62 (1), pp. 58-67. [Online].